ARIAD PHARMACEUTICALS INC 4
4 · Theseus Pharmaceuticals, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
TAKEDA PHARMACEUTICAL CO LTD
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2021-10-12−1,615,427→ 0 total(indirect: See explanation)→ Common Stock (1,615,427 underlying) - Conversion
Common Stock
2021-10-12+1,615,427→ 1,615,427 total(indirect: See explanation)
Footnotes (3)
- [F1]Each share of Series A Preferred Stock converted into shares of the Issuers Common Stock at the close of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock had no expiration date.
- [F2]This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.
- [F3]The reportable securities are owned directly by ARIAD Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited's beneficial ownership of these securities is comprised of the reportable securities owned by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.